Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma

Neuro-Oncology

Volumn 14, Issue 4, 2012, Pages 482-490

  Ulmer, Stephan ^a,b   Spalek, Klara ^c   Nabavi, Arya ^b   Schultka, Susan ^b   Mehdorn, H Maximillian ^b   Kesari, Santosh ^d   Drner, Lutz ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

diffusion weighted imaging; follow up; GLIADEL wafer; glioblastoma multiforme; MR imaging

Indexed keywords

CARMUSTINE; TEMOZOLOMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; GLIOBLASTOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD;

ANTINEOPLASTIC AGENTS, ALKYLATING; BIOCOMPATIBLE MATERIALS; BRAIN; BRAIN ABSCESS; BRAIN NEOPLASMS; CARMUSTINE; DECANOIC ACIDS; DIAGNOSTIC ERRORS; DIFFUSION MAGNETIC RESONANCE IMAGING; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; POLYESTERS; TIME FACTORS;

EID: 84859518530     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos003     Document Type: Article

References (45)

1. Boyle P, Levin B, ed. World Cancer Report 2008. Lyon: International Agency for Research on Cancer, 2008.
2. Rachet B, Mitry E, Quinn MJ, et al. Survival from brain tumours in England and Wales up to 2001. Br J Cancer. 2008;99(suppl 1):S98-S101.
3. UK Brain and Central Nervous System Cancer Incidence Statistics. 2008 September 9, 2008. Available from URL: http://info.cancerresearchuk. org/cancerstats/types/brain/incidence
4. Bauchet L, Rigau V, Mathieu-Daude H, et al. French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol. 2007;84(2):189-199. (Pubitemid 47202129)
5. Ekman M, Westphal M. Cost of brain tumour in Europe. Eur J Neurol. 2005;12(suppl 1):45-49. (Pubitemid 40755603)
6. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109(1):93-108. (Pubitemid 40287792)
7. Stupp R, Roila F. Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(suppl 2):ii83-ii85.
8. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology. 1980;30(9):907-911. (Pubitemid 10059239)
9. Kochi M, Ushio Y. High-dose chemotherapy with autologous hematopoietic stem-cell rescue for patients with malignant brain tumors. Crit Rev Neurosurg. 1999;9(5):295-302.
10. Petersdorf SH, Livingston RB. High dose chemotherapy for the treatment of malignant brain tumors. J Neurooncol. 1994;20(2): 155-163. (Pubitemid 24309910)
11. Zucchetti M, Boiardi A, Silvani A, et al. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother Pharmacol. 1999;44(2): 173-176. (Pubitemid 29297066)
12. Gumerlock MK, Belshe BD, Madsen R, et al. Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review. J Neurooncol. 1992;12(1):33-46.
13. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol. 2000;20(2):217-230. (Pubitemid 30091457)
14. Sant M, Aareleid T, Berrino F, et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol. 2003;14(suppl 5):v61-v118. (Pubitemid 46417464)
15. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479-489. (Pubitemid 40781150)
16. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. (Pubitemid 40349501)
17. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5): 459-466.
18. Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep. 1983;67(2):121-132. (Pubitemid 13110644)
19. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303(23):1323-1329. (Pubitemid 11194457)
20. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003; 5(2):79-88. (Pubitemid 36422560)
21. Lin SH, Kleinberg LR. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther. 2008;8(3):343-359. (Pubitemid 351836283)
22. Grossman SA, Reinhard C, Colvin OM, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg. 1992;76(4):640-647.
23. Dang W, Daviau T, Brem H. Morphological characterization of polyanhydride biodegradable implant gliadel during in vitro and in vivo erosion using scanning electron microscopy. Pharm Res. 1996; 13(5):683-691. (Pubitemid 26160095)
24. Fung LK, Ewend MG, Sills A, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res. 1998;58(4):672-684. (Pubitemid 28099477)
25. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet. 2002;41(6):403-419. (Pubitemid 34753678)
26. Sampath P, Brem H. Implantable Slow-Release Chemotherapeutic Polymers for the Treatment of Malignant Brain Tumors. Cancer Control. 1998;5(2):130-137. (Pubitemid 28178234)
27. Gururangan S, Cokgor L, Rich JN, et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol. 2001;3(4):246-250. (Pubitemid 33674145)
28. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995;345(8956):1008-1012.
29. Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien). 2006;148(3):269-275; discussion 75. (Pubitemid 43341024)
30. Do V, Gebski V, Barton MB. The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother Oncol. 2000;57(2):131-136.
31. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110(3):583-588.
32. Gliadel 7.7 mg ImplantSummary of Product Characteristics. 2008 June 23, 2008. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/ DisplayDoc.asp?DocumentID=13913. Accessed January 6, 2009.
33. Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin. 2008;24(11):3239-3257.
34. Dö rner L, Ulmer S, Rohr A, Mehdorn HM, Nabavi A. Space-occupying cyst development in the resection cavity of malignant gliomas following Gliadelw implantation-incidence, therapy strategies and outcome. J Clin Neurosci. 2011;18(3):347-351.
35. Engelhard HH. Tumor bed cyst formation after BCNU wafer implantation: report of two cases. Surg Neurol. 2000;53:220-224. (Pubitemid 30201525)
36. McGirt MJ, Villavicencio AT, Bulsara KR, et al. Management of tumor bed cysts after chemotherapeutic wafer implantation. J Neurosurg. 2002;96:941-945. (Pubitemid 34415410)
37. SPSS. Rel. 17.0.1. SPSS inc. Chicago. 2008.
38. Kaplan EL, Meier P. Nonparametric estimation from incomplete obervations. J Am Stat Assoc. 1958;53:457-481.
39. Cox DR. Regression models and life-tables. J R Stat Soc Ser B Stat Methodol. 1972;34:187-220.
40. Ulmer S, Braga TA, Barker FG, 2nd, Lev MH, Gonzalez RG, Henson JW. Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology. 2006;67(9):1668-1670. (Pubitemid 44747942)
41. Della Puppa A, Rossetto M, Ciccarino P, et al. The first 3 months after BCNU wafer implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series. Acta Neurochir (Wien). 2010;152(11):1923-1931.
42. Dyke JP, Sanelli PC, Voss HU, et al. Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla. J Neurooncol. 2007;82(1):103-110.
43. Fink J, Born D, Chamberlain MC. Pseudoprogression: relevance with respect to treatment of high-grade gliomas. Curr Treat Options Oncol. 2011;12(3):240-252.
44. Hammoud DA, Belden CJ, Ho AC, et al. The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging. AJR Am J Roentgenol. 2003;180(5):1469-1475. (Pubitemid 36504646)
45. Ewend MG. Polymer-based local therapy. December 7, 2007. Available from URL: http://www.gliomaed.com/topic-detail.asp?id=10. Accessed January 6, 2009.